ESR2 and in situ carcinoma: Protein expression of luminal (CK20, GATA3, ERβ, Her2) and basal (CK5/6, CK14) markers as well as of p53 was evaluated in 156 CIS specimens from 132 patients (104 men and 28 women) using IHC.